EMILY MARDEN is trained in the life sciences, and has a deep understanding of the most advanced scientific developments shaping drug and biologic therapeutics as well as innovations in the development of foods, dietary supplements, and agriculture. Emily’s practice focuses on regulatory and strategic questions at the cutting edge, including:
- Regenerative Medicine: clinical study, approval, and competitive issues associated with regenerative medicine (including gene therapy, cell therapy, and Public Health Service Act (PHSA) Section 361 products);
- Complex Drugs and Biological Products: approval and competitive issues associated with complex drugs (e.g., non-biological complex drugs, peptides) and biological products
- Genomics and Synthetic Biology: governance and international policy associated with genomics, gene editing, and synthetic biology in agriculture, food, drugs, and biological products;
- Regulatory Exclusivity: regulatory and strategic issues associated with Hatch-Waxman (New Chemical Entity, New Clinical Study, 180-day) and other (Orphan, Paediatric, Biological Product) exclusivities; and
- Innovations in Food and Agriculture: developments including novel and alternative ingredients derived from microbial, animal cell-based, and plant technologies.
In addition to her regulatory practice, Emily is an adjunct professor of Law at New York University School of Law, where she co-teaches Food and Drug Law and Policy. She has also led research projects on genomics and innovation in agriculture at The University of British Columbia and publishes and speaks widely on interrelated issues of policy, regulation, and innovation. Emily received degrees in biology and the history of science from Harvard University and University of Cambridge, and she received her J.D. from New York University School of Law.